Back to Insights and Updates for ProvidersApril 2024

Adalimumab biosimilar strategy for RITogether

Tufts Health RITogether

As previously communicated, effective April 1, 2024, the following FDA-approved adalimumab biosimilars have been added to the Tufts Health RITogether pharmacy formulary at preferred status with prior authorization:

  • Adalimumab-adbm
  • Adalimumab-fkjp
  • Hadlima

All other available FDA-approved adalimumab biosimilars and the reference product Humira (adalimumab) will be non-preferred products and non-covered effective April 1, 2024.

Audrey Kleinberg,
Director, Provider Relations & Communications

Annmarie Dadoly,
Senior Manager, Provider Communications

Joseph O’Riordan, Susan Panos, Ellen Gustavson, Ryan Francis, Stephen Wong,

Kristin Edmonston,
Production Coordinator

Kristina Cicelova,
Graphic Designer